Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Reckitt Group

(Sharecast News) - Analysts at Berenberg lowered their target price on household goods manufacturer Reckitt Group from 5,800.0p to 5,100.0p on Thursday, citing limited visibility going forward. Berenberg noted that Reckitt's Q1 results revealed that group like-for-like sales grew by 1.5%, ahead of visible alpha consensus expectations of a -1.1% decline, driven by a price/mix of 2.0% and a decline in volumes of only 0.5%, the latter of which was significantly better than the 3.3% expected.

At the divisional level, hygiene achieved like-for-like sales growth of 7.1%, while health like-for-like sales grew by 1.0% and nutrition declined by 9.9%, better than the 14.2% drop predicted by analysts. Actual group sales of £3.73bn also came in 1% ahead of consensus.

"After six quarters of mid-single-digit volume declines, the better-than-expected volume development in Q1 will likely lead some investors to review the investment case on Reckitt. The bull case, in our view, includes the potential return to volume growth, which appears closer than it did a few months ago (we now expect volumes to turn positive in Q3 versus Q4 previously). Growth from pricing could also prove more resilient, with management taking selective price increases this year and a constructive outlook on mix as innovation platforms seem to be supporting premiumisation within the company's Powerbrands. Therefore the earnings downgrade cycle may not persist into H2 2024 as we previously anticipated," said Berenberg.

"That being said, after years of significant volatility, the bear case includes limited visibility and risk to earnings from a deterioration in the consumer backdrop, unfavourable FX and earnings-dilutive business disposals. In addition, ongoing litigation risks relating to the necrotizing enterocolitis (NEC) trials in the US, could limit any short-term stock rerating."

In addition to lowering its target price on the stock, the German bank also reiterated its 'hold' rating on Reckitt shares.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Broker tips: NatWest, Helios Towers
(Sharecast News) - NatWest's share-price surge since the start of the year could well continue, according to analysts at Barclays, who hiked their target price for the stock on Thursday.
Broker tips: Astrazeneca, Mondi
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".
Broker tips: Shell, Standard Chartered, Team 17, AJ Bell
(Sharecast News) - RBC Capital Markets has raised its forecasts for Shell and kept an 'outperform' rating, saying the business was "firing on most cylinders" in the quarter.
Broker tips: Volution, Videndum
(Sharecast News) - Jefferies reiterated its 'buy' rating and 510.0p target price on Volution on Wednesday as it said the company's ability to drive margins higher, through both revenue mix and efficiency, is more than offsetting the challenging market backdrop to deliver ongoing earning upgrades.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.